KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Gross Margin (2020 - 2025)

Historic Gross Margin for Vir Biotechnology (VIR) over the last 6 years, with Q2 2025 value amounting to 99.09%.

  • Vir Biotechnology's Gross Margin rose 7800.0% to 99.09% in Q2 2025 from the same period last year, while for Jun 2025 it was 96.08%, marking a year-over-year decrease of 27200.0%. This contributed to the annual value of 98.86% for FY2024, which is 20700.0% up from last year.
  • Per Vir Biotechnology's latest filing, its Gross Margin stood at 99.09% for Q2 2025, which was up 7800.0% from 100.0% recorded in Q1 2025.
  • Vir Biotechnology's 5-year Gross Margin high stood at 100.0% for Q1 2021, and its period low was 31.28% during Q2 2022.
  • Moreover, its 5-year median value for Gross Margin was 97.44% (2024), whereas its average is 92.81%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -680400bps in 2022, then surged by 681400bps in 2023.
  • Quarter analysis of 5 years shows Vir Biotechnology's Gross Margin stood at 93.0% in 2021, then decreased by -6bps to 87.86% in 2022, then grew by 8bps to 95.25% in 2023, then decreased by -1bps to 94.47% in 2024, then rose by 5bps to 99.09% in 2025.
  • Its Gross Margin was 99.09% in Q2 2025, compared to 100.0% in Q1 2025 and 94.47% in Q4 2024.